Cell Therapy Manufacturing Market (7th Edition) by Type of Cell Therapy, Source of Cells, Origin of Cells, Technology, Scale of Operation, Type of Manufacturer, Key Geographical Regions

As per Roots Analysis, the global cell therapy manufacturing market is estimated to grow from USD 7.2 billion in the current year to USD 14.0 billion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 7.7% during the forecast period.

Cell Therapy Manufacturing Market - IMG1

Cell Therapy Manufacturing Market: Growth and Trends

Cell-based therapies have emerged as one of the most clinically transformative modalities in modern medicine. There are more than 1,000 cell and gene therapy candidates under active investigation, and close to 45 cell-based therapies have already been approved by regulatory authorities worldwide. As the treatment class matures from a patient-specific intervention into a scalable therapeutic category, developers are increasingly shifting to specialized manufacturing partners to increase cell therapy production.

The industry is undergoing a decisive shift toward closed, automated, and standardized manufacturing platforms intended to reduce manual intervention, improve batch-to-batch consistency, and support scale-out production models.

Further, the tariff exposure on pharmaceutical imports has accelerated investment in domestic advanced-therapy manufacturing infrastructure in the US, while emerging economies including India and Saudi Arabia are building local capacity to support affordable, regionally accessible cell therapy production. Collectively, these initiatives point to a market that is shifting from artisanal manufacturing toward a more standardized, distributable, and investable industrial category.

Growth Drivers: Factors Fueling Market Expansion

Growth in the cell therapy manufacturing market is being driven primarily by the rapidly expanding clinical pipeline. As of now, industry trackers identified over 2,100 gene therapy candidates (including genetically modified cell therapies such as CAR-T) and close to 1,000 non-genetically modified cell therapies in active development. This sustained pipeline expansion is translating directly into demand for specialized clinical and commercial scale manufacturing capacity.

Furthermore, companies focused on affordable cell therapy access, together with government-backed facility investments in markets such as India and Saudi Arabia, are extending manufacturing capacity beyond the traditional North American and European hubs. This initiative is widening the addressable market for equipment, consumables, and logistics partners over the long term.

Market Challenges: Critical Barriers Hindering Progress

Despite favourable demand fundamentals, the market faces several challenges that impede growth. The transition of cell-based therapies from laboratory to commercial scale is constrained by a shortage of skilled bioprocessing professionals, evolving regulatory requirements, and limited GMP manufacturing capacity.

Further, scale-up remains a key challenge as cell therapy manufacturing requires GMP-compliant cleanrooms and strict quality controls, increasing costs, timelines, and manufacturing complexity. Addressing these workforce, infrastructure, and regulatory harmonization gaps will be central to unlocking the market's full commercial potential.

Role of Tariffs on Domestic Production

Tariff measures on pharmaceutical imports have prompted a wave of agreements and capital commitments aimed at expanding US-based manufacturing. In May, the US Commerce Department opened an application process allowing pharmaceutical manufacturers to seek reduced Section 232 tariff rates in exchange for committing to expand or relocate manufacturing operations domestically. This policy shift is expected to reinforce continued investment in onshore advanced-therapy manufacturing infrastructure.

Cell Therapy Manufacturing Market: Key Insights

The report delves into the current state of the Cell Therapy Manufacturing market and identifies potential growth opportunities within the industry, particularly from a distributor and channel-partner perspective. Some key findings include:

Clinical Pipeline Momentum: Over 2,000+ active clinical trials are advancing cell therapies globally, sustaining long-term demand for clinical and commercial manufacturing capacity.
Manufacturing Partnerships Accelerating: More than 150 strategic collaborations have been announced in the past five years, primarily focused on manufacturing, process development, and technology integration.
Capacity Expansion Remains a Key Growth Strategy: Leading CDMOs and biopharma companies continue to invest in new GMP manufacturing facilities across North America, Europe, and Asia-Pacific to address anticipated commercial demand.
Automation Gaining Traction: Increasing adoption of closed-system and automated manufacturing platforms is improving scalability, reducing contamination risk, and lowering manufacturing costs.
Shift Toward Allogeneic Manufacturing: While autologous therapies currently dominate manufacturing demand, allogeneic cell therapies are expected to witness faster adoption owing to their off-the-shelf production potential.
Oncology Continues To Lead: Oncology remains the largest therapeutic focus, accounting for the majority of cell therapy clinical programs, with autoimmune and neurological disorders emerging as high-growth application areas.
North America Maintains Leadership: The region continues to account for the largest share of manufacturing activity, supported by a strong developer base, established CDMOs, and favourable investment ecosystem.
Investment Activity Remains Robust: Venture capital funding, strategic acquisitions, and government support continue to strengthen manufacturing infrastructure and accelerate commercialization of advanced cell therapies.

Cell Therapy Manufacturing Market Segments

Roots Analysis segments the global cell therapy manufacturing market opportunity across the following parameters:

By Type of Cell Therapy

CAR-T Cell Therapies
Stem Cell Therapies
TCR Therapies
TIL Therapies
Dendritic Cell Therapies
Other Cell Therapies

By Source of Cells

Autologous Cells
Allogeneic Cells

By Origin of Cells

Induced Pluripotent Stem Cells
Bone Marrow
Umbilical Cord
Adipose Tissue
Neural Stem Cells
Others

By Technology

Somatic Cell Technology
3D Bioprinting Technology
Cell Immortalization Technology
Viral Vector Technology
Genome Editing Technology
Cell Plasticity Technology

By Scale of Operation

Clinical Scale
Commercial Scale

By Type of Manufacturer

In-house Manufacturers
Contract Manufacturing Organizations

By Key Geographical Regions

North America
US
Canada
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific and Rest of the World
Argentina
Australia
Brazil
China
India
Israel
Japan
Singapore
South Africa
South Korea
Taiwan

Cell Therapy Manufacturing Market: Key Segment Insights

CAR-T Cell Therapies Lead the Market

Based on Roots Analysis market assessment and detailed clinical pipeline analysis, CAR-T cell therapies currently hold the highest share of the market. This dominance is driven by strong clinical and commercial adoption in hematological malignancies, an expanding portfolio of approved products, and the complex manufacturing processes associated with CAR-T therapies, which contribute significantly to overall market value.

Looking ahead, the other cell therapies segment including natural killer (NK) cell and genetically modified cell therapies will register the highest CAGR during the forecast period. This growth is driven by rising investment in next-generation cell therapy platforms designed to improve manufacturing scalability, reduce production costs, and expand patient access. Among these, natural killer (NK) cell therapies are gaining significant momentum owing to their allogeneic potential, favorable safety profile, lower risk of graft-versus-host disease, and suitability for off-the-shelf manufacturing.

Autologous Cells Continue to Dominate Source of Cells

According to our market analysis, autologous cells account for the largest share of the market and also register the highest CAGR during the forecast period. This growth is driven by the strong clinical adoption of patient-specific therapies, particularly within CAR-T manufacturing. Since autologous therapies use a patient's own cells, they reduce the risk of immune rejection and graft-versus-host disease. Recent approvals of autologous stem-cell-based gene therapies reinforce the continued clinical relevance of this approach.

Bone Marrow Leads Origin of Cells, iPSCs Poised for Fastest Growth

Bone marrow-derived cells currently account for the largest share of the market by origin of cells. This dominance is due to their long-established use in hematopoietic stem cell transplantation and well-defined collection, processing, and storage protocols. However, induced pluripotent stem cells (iPSCs) are expected to witness the strongest growth over the forecast period. This lucrative growth is due to their capacity to propagate indefinitely and differentiate into multiple specialized cell types, a property well suited to standardized, allogeneic, off-the-shelf manufacturing models.

Somatic Cell Technology Dominates, 3D Bioprinting Registers Higher CAGR

Somatic cell technology currently captures the largest share of the market. This highest share is due to its widespread use across isolation, processing, expansion, and modification workflows for CAR-T, TCR, dendritic cell, and stem cell based therapies. 3D bioprinting technology is expected to grow at the highest rate of any technology segment, driven by rising interest in personalized, tissue-mimetic cell-laden constructs for next-generation regenerative medicine applications.

Clinical-Scale Manufacturing Leads the Market While Commercial Scale Register Higher CAGR

Clinical-scale manufacturing currently captures the largest share of the market, reflecting the sheer volume of candidates still progressing through early and late stage trials. As more cell therapies advance toward approval and commercial launch, commercial-scale manufacturing capacity is expected to expand at a higher CAGR in the future, requiring sustained capital investment in cleanroom infrastructure and automation.

Contract Manufacturing Organizations Capture the Majority Share

CDMOs currently account for the majority of overall market revenue share. Outsourcing enables developers to reduce capital expenditure, accelerate clinical and commercial timelines, access advanced manufacturing technologies, and navigate complex regulatory requirements more efficiently. In contrast, in-house manufacturing remains concentrated among large, vertically integrated cell therapy companies with financial resources and technical expertise to establish and operate dedicated GMP-compliant manufacturing facilities.

North America Dominates the Market and Registers the Highest CAGR

North America currently captures the largest share of the cell therapy manufacturing market. This highest share is supported by a dense concentration of cell therapy developers, advanced GMP manufacturing infrastructure, established clinical research networks, and an increasingly flexible regulatory environment in the US. The region is also expected to register the fastest CAGR over the forecast period. This unprecedented growth is driven by continued capacity expansion including large-scale facility investments announced by both emerging and established players seeking next-generation manufacturing footprint in the US Northeast.

Example Players in Cell Therapy Manufacturing Market

Advanced Therapies
AGC Biologics
Astellas Pharma
Catalent
Charles River Laboratories
City of Hope
Clinical Cell and Vaccine Production Facility (CVPF)
Evotec
Fraunhofer Institute for Cell Therapy and Immunology
ImmunityBio
Lonza
Merck Millipore
Miltenyi Biotec
Minaris Advanced Therapies
Newcastle Advanced Therapies
NHS Blood and Transplant
OBiO Tech
Pharmaron
Rayne Cell Therapy Suite
Resilience
Sartorius
Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
SK pharmteco (Subsidiary of SK Inc.)
Takara Bio
Thermo Fisher Scientific

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Executive Officer, Mid-sized Company, UK
Group Executive, Bioprocess, Very Large Company, US
Former Chief Technical Officer, Large Company, US
Vice President & Head of Quality & Compliance, Mid-sized Company, US
Executive Director, Global Scientific Portfolio Management, Cell and Gene Therapy, Very Large Company, US
Professor and American Red Cross Chair in Transfusion Medicine, US
Senior Director of Sales, Advanced Therapies, Small Company, US
Principal Scientist, Process Development Services, Very Large Company, Germany

CELL THERAPY MANUFACTURING MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: An in-depth, top-down and bottom-up triangulated analysis of the market focusing on key segments, including type of cell therapy, source of cells, origin of cells, technology, scale of operation, type of manufacturer, and geographical regions.
Industry and Non-Industry Player Landscape: A detailed assessment of both commercial (industry) and academic / non-profit (non-industry) cell therapy manufacturers, featuring year of establishment, company size, location of headquarters and manufacturing facilities, type of immune cell offered, source of cells, and scale of operation.
Regulatory Landscape: A review of current regulatory guidelines across North America, Europe, and Asia-Pacific, including conditional approval pathways and the variability in requirements across geographies.
Case Study I (Roadmaps for Overcoming Manufacturing Challenges): A focused assessment of roadmaps for cell processing, preservation, automation, quality control, standardization, workforce development, and supply chain across the US and other geographies.
Case Study II (Automation Technologies): An evaluation of closed, single-use, and modular automation systems, including growth drivers, roadblocks, and case studies of automated manufacturing device development.
Company Profiles: In-depth profiles of prominent industry and non-industry players, covering company overview, financial information, service portfolio, manufacturing facilities and capabilities, and recent developments.
Non-Profit Organizations: An overview of non-profit and consortium-based cell therapy manufacturing initiatives and international societies active in the domain.
Clinical Trial Analysis: A comprehensive analysis of cell therapy clinical trials by registration year, status, phase, study design, sponsor type, most active players, and geography.
Partnerships and Collaborations: An analysis of partnerships inked by cell therapy manufacturers, based on year, type of partnership, type of immune cell, scale of operation, most active players, and geography.
Recent Expansions Analysis: A comprehensive assessment of recent facility expansion initiatives by type, year, location, and immune cell focus, identifying the most active companies by number of expansions and area added.
Big Pharma Initiatives: An analysis of initiatives undertaken by leading pharmaceutical companies, covering partnerships, M&A, facility expansions, and funding activity, and identifying the most active big pharma players.
Capacity Analysis: A comprehensive assessment of global installed cleanroom capacity (number and area) across company size, scale of operation, and geography, for both industry and non-industry players.
Demand Analysis: An evaluation of global clinical and commercial demand for cell therapy manufacturing, segmented by type of cell therapy and geography.
Cost Price Analysis: An assessment of the factors driving high cell therapy pricing, pricing models, cost optimization levers, the role of CDMOs, and reimbursement considerations, including a NICE CAR-T appraisal case study.
SWOT Analysis: A strategic assessment of the market's strengths, weaknesses, opportunities, and threats, with a comparative Harvey Ball analysis.
Survey Analysis: Primary survey insights on respondent designation, type of cell therapy, scale of operation, source of cells, cell culture system, and fill / finish service availability.
Executive Insights: Company snapshots and interview transcripts capturing the perspectives of senior industry and non-industry stakeholders.

Key Questions Answered in this Report

Which are the leading companies in the cell therapy manufacturing market?
Which region dominates the market, and which is growing the fastest?
What are the key trends observed in this market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by cell therapy manufacturers?
What is the current and future market size?
What is the CAGR of this market through 2035?
How is current and future market opportunity distributed across key segments?
What opportunities exist for distributors and logistics partners entering this space?

Reasons to Buy this Report

This report has been specifically developed to support distributors, channel partners, and business development teams evaluating entry into the cell therapy manufacturing market.

Top-Down and Bottom-Up Triangulated Forecasting: Market estimates are built using a hybrid methodology that cross-validates top-down macro assessments against bottom-up, company-level capacity and demand data, minimizing forecast bias.
656 Pages Across 40 Chapters: Comprehensive coverage spanning market sizing, competitive benchmarking, clinical trial activity, capacity, demand, funding and M&A analysis, and regulatory mapping across 25+ countries.
Primary Research-Backed Insights: Findings are validated through direct interviews with CEOs, CTOs, and commercial leaders across 34 industry and non-industry organizations, ensuring insights reflect real operating conditions rather than desk research alone.
Actionable Segmentation: Seven-parameter segmentation (type of cell therapy, source of cells, origin of cells, technology, scale of operation, type of manufacturer, geography) enables precise opportunity sizing for any go-to-market or investment thesis.

Additional Benefits

Complementary Insights Pack
Complementary PPT Insights Pack
Complementary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100392

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Chapter Overview
6.2. Introduction to Cell-based Therapies
- 6.2.1. Comparison of Cell-based Therapies and Other Biotechnology Products
- 6.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
- 6.2.3. Current Market Landscape of ATMPs
6.3. Overview of Cell Therapy Manufacturing
6.4. Cell Therapy Manufacturing Models
- 6.4.1. Centralized Manufacturing
- 6.4.2. Decentralized Manufacturing
6.5. Scalability of Cell Therapy Manufacturing Processes
- 6.5.1. Scale-up
- 6.5.2. Scale-out
6.6. Types of Cell Therapy Manufacturers
6.7. Key Challenges for Manufacturing Cell Therapies
6.8. Key Factors Influencing Cell Therapy Manufacturing
- 6.8.1. Cell Characterization
- 6.8.2. Cost of Goods
6.9. Automation of Cell Therapy Manufacturing
6.10. Cell Therapy Manufacturing Supply Chain
6.11. Future Perspectives

7. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Industry Players: Overall Market Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters (Region)
- 7.2.4. Analysis by Location of Headquarters (Country)
- 7.2.5. Analysis by Company Size and Location of Headquarters (Region)
- 7.2.6. Analysis by Location of Manufacturing Facility
- 7.2.7. Analysis by Type of Immune Cell Offered
- 7.2.8. Analysis by Source of Cells
- 7.2.9. Analysis by Scale of Operation
- 7.2.10. Analysis by Type of Additional Service Offered

8. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

8.1. Chapter Overview
8.2. Non-Industry Players: Overall Market Landscape
- 8.2.1. Analysis by Year of Establishment
- 8.2.2. Analysis by Location of Headquarters (Region)
- 8.2.3. Analysis by Location of Headquarters (Country)
- 8.2.4. Analysis by Location of Manufacturing Facility
- 8.2.5. Analysis by Type of Immune Cell Offered
- 8.2.6. Analysis by Source of Cell
- 8.2.7. Analysis by Scale of Operation
- 8.2.8. Analysis by Type of Additional Service Offered

9. REGULATORY LANDSCAPE

9.1. Chapter Overview
9.2. Current Scenario
- 9.2.1. Regulatory Guidelines in North America
- 9.2.2. Regulatory Guidelines in Europe
- 9.2.3. Regulatory Guidelines in Asia-Pacific
  - 9.2.3.1. Regulatory Guidelines in Japan
  - 9.2.3.2. Regulatory Guidelines in China
- 9.2.4. Conditional Approvals
9.3. Regulatory Authorities for Cell Therapy Manufacturing
- 9.3.1. Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
9.4. Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
9.5. Existing Challenges to Early-Stage Manufacturing of Cell Therapies
9.6. Variability in Regulatory Guidelines across Different Geographies

10. CASE STUDY: ROADMAPS FOR OVERCOMING CHALLENGES RELATED TO CELL THERAPY MANUFACTURING

10.1. Chapter Overview
10.2. Roadmap for the US
- 10.2.1. Cell Processing
- 10.2.2. Cell Preservation, Distribution and Handling
- 10.2.3. Process Automation and Data Analytics
- 10.2.4. Process Monitoring and Quality Control
- 10.2.5. Standardization and Regulatory Support
- 10.2.6. Workforce Development
- 10.2.7. Supply Chain and Logistics
10.3. Roadmaps for Other Geographies
- 10.3.1. Europe
- 10.3.2. Asia-Pacific

11. CASE STUDY: AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

11.1. Chapter Overview
11.2. Automation of Cell Therapy Manufacturing Processes
- 11.2.1. Closed Systems
- 11.2.2. Single-use Systems
- 11.2.3. Modular Systems
11.3. Growth Drivers and Roadblocks
11.4. Case Studies
- 11.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
- 11.4.2. Automating the Cell Therapy Manufacturing Process
- 11.4.3. Advancement to Automation of Cell Therapy Manufacturing Process
- 11.4.4. GMP-in-a-Box
- 11.4.5. List of Automated and Closed Cell Therapy Processing Systems

12. COMPANY PROFILES: INDUSTRY PLAYERS

12.1. Chapter Overview
12.2. Service Providers in North America
- 12.2.1. Advanced Therapies
  - 12.2.1.1. Company Overview
  - 12.2.1.2. Financial Information
  - 12.2.1.3. Service Portfolio
  - 12.2.1.4. Manufacturing Facilities and Capabilities
  - 12.2.1.5. Recent Developments and Future Outlook
- Similar details are presented for other below mentioned players based on information in the public domain
- 12.2.2. AGC Biologics
- 12.2.3. Catalent
- 12.2.4. Charles River Laboratories
- 12.2.5. ImmunityBio
- 12.2.6. Merck Millipore
- 12.2.7. Minaris Advanced Therapies
- 12.2.8. Resilience
- 12.2.9. SK pharmteco (Subsidiary of SK Inc.)
- 12.2.10. Thermo Fisher Scientific
12.3. Service Providers in Europe
- 12.3.1. Evotec
- 12.3.2. Lonza
- 12.3.3. Miltenyi Biotec
- 12.3.4. Sartorius
12.4. Service Providers in Asia-Pacific
- 12.4.1. Astellas Pharma
- 12.4.2. OBiO Tech
- 12.4.3. Pharmaron
- 12.4.4. Takara Bio

13. COMPANY PROFILES: NON-INDUSTRY PLAYERS

13.1. Chapter Overview
13.2. City of Hope
- 13.2.1. Overview
- 13.2.2. Service Portfolio
- 13.2.3. Type of Additional Service Offered
similar details are presented for other below mentioned players based on information in the public domain
13.3. Clinical Cell and Vaccine Production Facility (CVPF)
13.4. Fraunhofer Institute for Cell Therapy and Immunology
13.5. Newcastle Advanced Therapies
13.6. NHS Blood and Transplant
13.7. Rayne Cell Therapy Suite (King's College London)
13.8. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility

14. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING

14.1. Chapter Overview
14.2. Cell Therapy Manufacturing: Non-Profit Organizations
- 14.2.1. CellCAN
- 14.2.2. Cell Therapy Manufacturing Cooperative Research Center
- 14.2.3. National Cell Manufacturing Consortium (NCMC)
- 14.2.4. California Institute of Regenerative Medicine (CIRM)
14.3. Cell Therapy Manufacturing: International Societies

15. CLINICAL TRIAL ANALYSIS

15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Cell Therapies: Clinical Trial Analysis
- 15.3.1. Analysis by Trial Registration Year
- 15.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
- 15.3.3. Analysis by Trial Status
- 15.3.4. Analysis by Trial Registration Year and Trial Status
- 15.3.5. Analysis by Trial Phase
- 15.3.6. Analysis of Enrolled Patient Population by Trial Phase
- 15.3.7. Analysis by Patient Gender
- 15.3.8. Analysis by Study Design
  - 15.3.8.1. Analysis by Type of Allocation
  - 15.3.8.2. Analysis by Intervention Model
  - 15.3.8.3. Analysis by Type of Masking
- 15.3.9. Analysis by Type of Sponsor / Collaborator
- 15.3.10. Most Active Players: Analysis by Number of Registered Trials
- 15.3.11. Analysis by Geography
  - 15.3.11.1. Analysis of Clinical Trials by Geography
  - 15.3.11.2. Analysis of Clinical Trials by Trial Status and Geography
  - 15.3.11.3. Analysis of Enrolled Patient Population by Trial Status and Geography

16. PARTNERSHIPS AND COLLABORATIONS

16.1. Chapter Overview
16.2. Partnership Models
16.3. Cell Therapy Manufacturing: List of Partnerships
- 16.3.1. Analysis by Year of Partnership
- 16.3.2. Analysis by Type of Partnership
- 16.3.3. Analysis by Year and Type of Partnership
16.4. Analysis by Type of Immune Cell Offered
16.5. Analysis by Scale of Operation
16.6. Most Active Players: Analysis by Number of Partnerships
16.7. Analysis by Geography
- 16.7.1. Local and International Agreements
- 16.7.2. Intracontinental and Intercontinental Agreements

17. RECENT EXPANSIONS

17.1. Chapter Overview
17.2. Type of Expansions
17.3. Cell Therapy Manufacturing: Recent Expansions
- 17.3.1. Analysis by Year of Expansion
- 17.3.2. Analysis by Type of Expansion
- 17.3.3. Analysis by Year and Type of Expansion
- 17.3.4. Analysis by Location of Expanded Facility (Region)
- 17.3.5. Analysis by Location of Expanded Facility (Country)
- 17.3.6. Analysis by Type of Expansion and Location of Headquarters (Country)
- 17.3.7. Analysis by Type of Immune Cell Offered
- 17.3.8. Analysis by Type of Expansion and Type of Immune Cell Offered
- 17.3.9. Analysis by Scale of Operation
- 17.3.10. Most Active Players: Analysis by Number of Expansions
- 17.3.11. Most Active Players: Analysis by Area of Expansion

18. BIG PHARMA INITIATIVES

18.1. Chapter Overview
18.2. Cell Therapy Manufacturing: List of Big Pharma Players
18.3. Cell Therapy Manufacturing: List of Initiatives by Big Pharma Players
- 18.3.1. Analysis by Year of Initiative
- 18.3.2. Analysis by Type of Initiative
- 18.3.3. Analysis by Year and Type of Initiative
- 18.3.4. Big Players: Analysis by Number of Initiatives
- 18.3.5. Analysis by Type of Partnership
- 18.3.6. Big Players: Analysis by Number of Partnerships
- 18.3.7. Analysis by Type of Facility Expansion
- 18.3.8. Big Players: Analysis by Number of Facility Expansions
- 18.3.9. Big Players: Analysis by Region of Facility Expansion
- 18.3.10. Big Players: Analysis by Number of Mergers and Acquisitions
- 18.3.11. Big Players: Analysis by Number of Funding and Investment
- 18.3.12. Analysis by Type of Immune Cell Offered
- 18.3.13. Analysis by Scale of Operation
- 18.3.14. Analysis of Big Pharma Players by Scale of Operation
- 18.3.15. Big Pharma Initiatives Summary

19. CAPACITY ANALYSIS

19.1. Chapter Overview
19.2. Industry Players: Key Assumptions and Methodology
- 19.2.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
  - 19.2.1.1. Analysis by Company Size
  - 19.2.1.2. Analysis by Scale of Operation
  - 19.2.1.3. Analysis by Location of Manufacturing Facility
  - 19.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
  - 19.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility
- 19.2.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
  - 19.2.2.1. Analysis by Company Size
  - 19.2.2.2. Analysis by Scale of Operation
  - 19.2.2.3. Analysis by Location of Manufacturing Facility
  - 19.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
  - 19.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility
19.3. Non-Industry Players: Key Assumptions and Methodology
- 19.3.1. Cell Therapy Manufacturing: Global Installed Capacity (Number of Cleanrooms)
  - 19.3.1.1. Analysis by Scale of Operation
  - 19.3.1.2. Analysis by Location of Manufacturing Facility
- 19.3.2. Cell Therapy Manufacturing: Global Installed Capacity (Cleanroom Area)
  - 19.3.2.1. Analysis by Scale of Operation
  - 19.3.2.2. Analysis by Location of Manufacturing Facility
19.4. Concluding Remarks

20. DEMAND ANALYSIS

20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Global Demand for Cell Therapy Manufacturing
20.4. Global Clinical Demand for Cell Therapy Manufacturing
- 20.4.1. Clinical Demand: Analysis by Type of Cell Therapy
- 20.4.2. Clinical Demand: Analysis by Geography
20.5. Global Commercial Demand for Cell Therapy Manufacturing
- 20.5.1. Commercial Demand: Analysis by Type of Cell Therapy
- 20.5.2. Commercial Demand: Analysis by Geography

21. COST PRICE ANALYSIS

21.1. Chapter Overview
21.2. Factors Contributing to the High Price of Cell Therapies
21.3. Pricing Models for Cell Therapies
- 21.3.1. Based on Associated Costs for T-cell Therapies
- 21.3.2. Based on Associated Costs for Stem Cell Therapies
- 21.3.3. Based on Availability of Competing Products
- 21.3.4. Based on Target Patient Segment
- 21.3.5. Based on the Opinions of Industry Experts
21.4. Cell Therapy Cost Optimization
- 21.4.1. Role of Cost of Goods Sold
- 21.4.2. Role of Automation
21.5. Role of Cell Therapy Contract Manufacturing Organizations
21.6. Reimbursement-related Considerations for Cell Therapies
- 21.6.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

22. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

22.1. Chapter Overview
22.2. Assumptions and Key Parameters
22.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
- 22.3.1. Scenario 1
- 22.3.2. Scenario 2
- 22.3.3. Scenario 3
- 22.3.4. Scenario 4

23. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS

23.1. Chapter Overview
23.2. Key Parameters
23.3. Assumptions and Methodology
23.4. Sample Dataset for the Estimation of Total Cost of Ownership
23.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
23.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
- 23.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
- 23.6.2. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20

24. SWOT ANALYSIS

24.1. Chapter Overview
24.2. Strengths
24.3. Weaknesses
24.4. Opportunities
24.5. Threats
24.6. Comparison of SWOT Factors

25. SURVEY ANALYSIS

25.1. Chapter Overview
25.2. Analysis by Designation of Respondents
25.3. Analysis by Type of Cell Therapy
25.4. Analysis by Scale of Operation
25.5. Analysis by Source of Cells
25.6. Analysis by Type of Cell Culture System Used
25.7. Analysis by Availability of Fill / Finish Services

26. GLOBAL CELL THERAPY MANUFACTURING MARKET

26.1. Chapter Overview
26.2. Assumptions and Methodology
26.3. Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
26.4. Roots Analysis Perspective on Market Growth
26.5. Scenario Analysis
- 26.5.1. Conservative Scenario
- 26.5.2. Optimistic Scenario
26.6. Key Market Segmentations

27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
- 27.3.1. Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.2. Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.3. Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.4. Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.5. Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 27.3.6. Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation

28. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Cell Therapy Manufacturing Market: Distribution by Source of Cells
- 28.3.1. Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 28.3.2. Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation

29. CELL THERAPY MANUFACTURING MARKET, BY ORIGIN OF CELLS

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Cell Therapy Manufacturing Market: Distribution by Origin of Cells
- 29.3.1. Cell Therapy Manufacturing Market for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.2. Cell Therapy Manufacturing Market for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.3. Cell Therapy Manufacturing Market for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.4. Cell Therapy Manufacturing Market for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.5. Cell Therapy Manufacturing Market for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 29.3.6. Cell Therapy Manufacturing Market for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation

30. CELL THERAPY MANUFACTURING MARKET, BY TECHNOLOGY

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Cell Therapy Manufacturing Market: Distribution by Technology
- 30.3.1. Cell Therapy Manufacturing Market for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.2. Cell Therapy Manufacturing Market for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.3. Cell Therapy Manufacturing Market for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.4. Cell Therapy Manufacturing Market for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.5. Cell Therapy Manufacturing Market for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 30.3.6. Cell Therapy Manufacturing Market for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation

31. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Cell Therapy Manufacturing Market: Distribution by Scale of Operation
- 31.3.1. Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 31.3.2. Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
31.4. Data Triangulation and Validation

32. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER

32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
- 32.3.1. Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 32.3.2. Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
32.4. Data Triangulation and Validation

33. CELL THERAPY MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

33.1. Chapter Overview
33.2. Key Assumptions and Methodology
33.3. Cell Therapy Manufacturing Market: Distribution by Key Geographical Regions
- 33.3.1. Clinical Cell Therapy Manufacturing Market
  - 33.3.1.1. Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.1.1. Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.1.2. Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  - 33.3.1.2. Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.2.1. Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.2.2. Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.2.3. Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.2.4. Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.2.5. Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  - 33.3.1.3. Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.1. Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.2. Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.3. Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.4. Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.5. Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.6. Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.7. Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.8. Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.1.3.9. Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 33.3.2. Commercial Cell Therapy Manufacturing Market
  - 33.3.2.1. Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.1.1. Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.1.2. Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  - 33.3.2.2. Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.2.1. Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.2.2. Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.2.3. Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.2.4. Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.2.5. Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.2.6. Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
  - 33.3.2.3. Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.3.1. Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.3.2. Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.3.3. Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.3.4. Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.3.5. Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
    - 33.3.2.3.6. Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
33.4. Penetration Growth (P-G) Matrix
33.5. Market Dynamics Assessment

34. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

34.1. Cell Therapy Manufacturing Market in North America: Distribution by Type of Cell Therapy
- 34.1.1. Cell Therapy Manufacturing Market in North America for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.2. Cell Therapy Manufacturing Market in North America for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.3. Cell Therapy Manufacturing Market in North America for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.4. Cell Therapy Manufacturing Market in North America for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.5. Cell Therapy Manufacturing Market in North America for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.1.6. Cell Therapy Manufacturing Market in North America for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.2. Cell Therapy Manufacturing Market in North America: Distribution by Source of Cells
- 34.2.1. Cell Therapy Manufacturing Market in North America for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.2.2. Cell Therapy Manufacturing Market in North America for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.3. Cell Therapy Manufacturing Market in North America: Distribution by Origin of Cells
- 34.3.1. Cell Therapy Manufacturing Market in North America for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.2. Cell Therapy Manufacturing Market in North America for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.3. Cell Therapy Manufacturing Market in North America for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.4. Cell Therapy Manufacturing Market in North America for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.5. Cell Therapy Manufacturing Market in North America for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.3.6. Cell Therapy Manufacturing Market in North America for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.4. Cell Therapy Manufacturing Market in North America: Distribution by Technology
- 34.4.1. Cell Therapy Manufacturing Market in North America for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.2. Cell Therapy Manufacturing Market in North America for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.3. Cell Therapy Manufacturing Market in North America for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.4. Cell Therapy Manufacturing Market in North America for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.5. Cell Therapy Manufacturing Market in North America for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.4.6. Cell Therapy Manufacturing Market in North America for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.5. Cell Therapy Manufacturing Market in North America: Distribution by Scale of Operation
- 34.5.1. Cell Therapy Manufacturing Market in North America for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.5.2. Cell Therapy Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
34.6. Cell Therapy Manufacturing Market in North America: Distribution by Type of Manufacturer
- 34.6.1. Cell Therapy Manufacturing Market in North America for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 34.6.2. Cell Therapy Manufacturing Market in North America for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)

35. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: EUROPE

35.1. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Cell Therapy
- 35.1.1. Cell Therapy Manufacturing Market in Europe for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.2. Cell Therapy Manufacturing Market in Europe for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.3. Cell Therapy Manufacturing Market in Europe for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.4. Cell Therapy Manufacturing Market in Europe for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.5. Cell Therapy Manufacturing Market in Europe for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.1.6. Cell Therapy Manufacturing Market in Europe for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.2. Cell Therapy Manufacturing Market in Europe: Distribution by Source of Cells
- 35.2.1. Cell Therapy Manufacturing Market in Europe for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.2.2. Cell Therapy Manufacturing Market in Europe for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.3. Cell Therapy Manufacturing Market in Europe: Distribution by Origin of Cells
- 35.3.1. Cell Therapy Manufacturing Market in Europe for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.2. Cell Therapy Manufacturing Market in Europe for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.3. Cell Therapy Manufacturing Market in Europe for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.4. Cell Therapy Manufacturing Market in Europe for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.5. Cell Therapy Manufacturing Market in Europe for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.3.6. Cell Therapy Manufacturing Market in Europe for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.4. Cell Therapy Manufacturing Market in Europe: Distribution by Technology
- 35.4.1. Cell Therapy Manufacturing Market in Europe for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.2. Cell Therapy Manufacturing Market in Europe for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.3. Cell Therapy Manufacturing Market in Europe for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.4. Cell Therapy Manufacturing Market in Europe for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.5. Cell Therapy Manufacturing Market in Europe for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.4.6. Cell Therapy Manufacturing Market in Europe for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.5. Cell Therapy Manufacturing Market in Europe: Distribution by Scale of Operation
- 35.5.1. Cell Therapy Manufacturing Market in Europe for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.5.2. Cell Therapy Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
35.6. Cell Therapy Manufacturing Market in Europe: Distribution by Type of Manufacturer
- 35.6.1. Cell Therapy Manufacturing Market in Europe for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 35.6.2. Cell Therapy Manufacturing Market in Europe for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)

36. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

36.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Cell Therapy
- 36.1.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.1.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Source of Cells
- 36.2.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.2.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Origin of Cells
- 36.3.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.3.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Technology
- 36.4.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.3. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.4. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.4.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.5. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
- 36.5.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.5.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
36.6. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World: Distribution by Type of Manufacturer
- 36.6.1. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
- 36.6.2. Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035)
*Detailed information on Chapters 34-36 is available in the Excel Data Packs shared along with the report**

37. CONCLUDING REMARKS

38. EXECUTIVE INSIGHTS

39. APPENDIX I: TABULATED DATA

40. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100392

List of Tables

Table 6.1 Cell-based Therapies: Applications
Table 6.2 Differences between Cell Therapy and Biotechnological Products
Table 6.3 Cell-based Therapies: Commercialized Products
Table 6.4 Assessment of Cell Therapy Manufacturing Steps
Table 6.5 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 7.1 Industry Players: Information on Year of Establishment, Company Size, Location of Headquarters, Number of Manufacturing Facilities and Location of Manufacturing Facility
Table 7.2 Industry Players: Information on Type of Immune Cell Offered
Table 7.3 Industry Players: Information on Source of Cells and Scale of Operation
Table 7.4 Industry Players: Information on Type of Additional Service Offered
Table 8.1 Non-Industry Players: Information on Year of Establishment, Location of Headquarters, Number of Manufacturing Facilities and Location of Manufacturing Facility
Table 8.2 Non-Industry Players: Information on Type of Immune Cell Offered
Table 8.3 Non-Industry Players: Information on Source of Cell and Scale of Operation
Table 8.4 Non-Industry Players: Information on Type of Additional Service Offered
Table 9.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
Table 9.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
Table 9.3 Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
Table 10.1 Cell Therapy Manufacturing: Roadmap for the US
Table 10.2 Cell Processing: Challenges and Strategies
Table 10.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
Table 10.4 Process Monitoring and Quality Control: Challenges and Strategies
Table 10.5 Standardization and Regulatory Support: Challenges and Strategies
Table 10.6 Workforce Development: Challenges and Strategies
Table 10.7 Supply Chain and Logistics: Challenges and Strategies
Table 10.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
Table 11.1 Cell Therapy Manufacturing: List of Automated and Closed Cell Therapy Processing Systems
Table 12.1 Cell Therapy Manufacturing Industry Players: List of Companies Profiled
Table 12.2 Advanced Therapies: Company Snapshot
Table 12.3 Advanced Therapies: Information on Manufacturing Facilities and Capabilities
Table 12.4 Advanced Therapies: Recent Developments and Future Outlook
Table 12.5 AGC Biologics: Company Snapshot
Table 12.6 AGC Biologics: Information on Manufacturing Facilities and Capabilities
Table 12.7 AGC Biologics: Recent Developments and Future Outlook
Table 12.8 Catalent: Company Snapshot
Table 12.9 Catalent: Information on Manufacturing Facilities and Capabilities
Table 12.10 Catalent: Recent Developments and Future Outlook
Table 12.11 Charles River Laboratories: Company Snapshot
Table 12.12 Charles River Laboratories: Information on Manufacturing Facilities and Capabilities
Table 12.13 Charles River Laboratories: Recent Developments and Future Outlook
Table 12.14 ImmunityBio: Company Snapshot
Table 12.15 ImmunityBio: Information on Manufacturing Facilities and Capabilities
Table 12.16 ImmunityBio: Recent Developments and Future Outlook
Table 12.17 Merck Millipore: Company Snapshot
Table 12.18 Merck Millipore: Information on Manufacturing Facilities and Capabilities
Table 12.19 Merck Millipore: Recent Developments and Future Outlook
Table 12.20 Minaris Advanced Therapies: Company Snapshot
Table 12.21 Minaris Advanced Therapies: Information on Manufacturing Facilities and Capabilities
Table 12.22 Minaris Advanced Therapies: Recent Developments and Future Outlook
Table 12.23 Resilience: Company Snapshot
Table 12.24 Resilience: Information on Manufacturing Facilities and Capabilities
Table 12.25 Resilience: Recent Developments and Future Outlook
Table 12.26 SK pharmteco (Subsidiary of SK Inc.): Company Snapshot
Table 12.27 SK pharmteco (Subsidiary of SK Inc.): Information on Manufacturing Facilities and Capabilities
Table 12.28 SK pharmteco (Subsidiary of SK Inc.): Recent Developments and Future Outlook
Table 12.29 Thermo Fisher Scientific: Company Snapshot
Table 12.30 Thermo Fisher Scientific: Information on Manufacturing Facilities and Capabilities
Table 12.31 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 13.1 Cell Therapy Manufacturing (Non-Industry Players): List of Organizations Profiled
Table 13.2 City of Hope: Overview
Table 13.3 City of Hope: Service Portfolio
Table 13.4 Clinical Cell and Vaccine Production Facility (CVPF): Overview
Table 13.5 Clinical Cell and Vaccine Production Facility (CVPF): Service Portfolio
Table 13.6 Fraunhofer Institute for Cell Therapy and Immunology: Overview
Table 13.7 Fraunhofer Institute for Cell Therapy and Immunology: Service Portfolio
Table 13.8 Newcastle Advanced Therapies: Overview
Table 13.9 Newcastle Advanced Therapies: Service Portfolio
Table 13.10 NHS Blood and Transplant: Overview
Table 13.11 NHS Blood and Transplant: Service Portfolio
Table 13.12 Rayne Cell Therapy Suite (King's College London): Overview
Table 13.13 Rayne Cell Therapy Suite (King's College London): Service Portfolio
Table 13.14 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Overview
Table 13.15 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Service Portfolio
Table 14.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
Table 14.2 CellCAN: Overview
Table 14.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
Table 14.4 National Cell Manufacturing Consortium: Overview
Table 14.5 California's Institute of Regenerative Medicine: Overview
Table 16.1 Cell Therapy Manufacturing: List of Partnerships and Collaborations
Table 16.2 Partnerships and Collaborations: Information on Type of Immune Cell Offered and Scale of Operation
Table 16.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 17.1 Cell Therapy Manufacturing: List of Expansions
Table 17.2 Cell Therapy Manufacturing: Type of Immune Cell Offered and Scale of Operation
Table 18.1 List of Top 10 Big Pharma Players
Table 18.2 Big Pharma Players: List of Cell Therapy Manufacturing Focused Initiatives, Since 2021
Table 18.3 Big Pharma Initiatives: Information on Type of Immune Cell Offered and Scale of Operation
Table 19.1 Average Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Sample Data Set for Industry Players
Table 19.2 Average Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Sample Data Set for Industry Players
Table 19.3 Global Installed capacity of industry players for cell therapy manufacturing (Number of Cleanrooms): Distribution by Company Size
Table 19.4 Global Installed capacity of industry players for cell therapy manufacturing (Cleanroom Area): Distribution by Company Size
Table 19.5 Median Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Data Set for Non-Industry Players
Table 19.6 Median Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Dat Set for Non-Industry Players
Table 21.1 Costs Associated with Manufacturing Stem Cell Therapies
Table 21.2 Pricing Model: Price of Marketed Drugs (Antibody Drug Conjugates and Monoclonal Antibodies)
Table 21.3 T-cell Immunotherapies: Expert Opinions on Pricing
Table 21.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 23.1 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Table 23.2 Total Cost of Ownership: Sample Dataset
Table 25.1 Survey Insights: Overview of Respondents
Table 25.2 Survey Insights: Designations and Seniority Levels
Table 25.3 Survey Insights: Type of Cell Therapy
Table 25.4 Survey Insights: Scale of Operation
Table 25.5 Survey Insights: Source of Cells
Table 25.6 Survey Insights: Cell Culture System
Table 25.7 Survey Insights: Availability of Fill / Finish Services
Table 39.1 Industry Players: Distribution by Year of Establishment
Table 39.2 Industry Players: Distribution by Company Size
Table 39.3 Industry Players: Distribution by Location of Headquarters (Region)
Table 39.4 Industry Players: Distribution by Location of Headquarters (Country)
Table 39.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
Table 39.6 Industry Players: Distribution by Location of Manufacturing Facility (Region)
Table 39.7 Industry Players: Distribution by Location of Manufacturing Facility (Country)
Table 39.8 Industry Players: Distribution by Type of Immune Cell Offered
Table 39.9 Industry Players: Distribution by Source of Cells
Table 39.10 Industry Players: Distribution by Scale of Operation
Table 39.11 Industry Players: Distribution by Type of Additional Service Offered
Table 39.12 Non-Industry Players: Distribution by Year of Establishment
Table 39.13 Non-Industry Players: Distribution by Location of Headquarters (Region)
Table 39.14 Non-Industry Players: Distribution by Location of Headquarters (Country)
Table 39.15 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
Table 39.16 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
Table 39.17 Non-Industry Players: Distribution by Type of Immune Cell Offered
Table 39.18 Non-Industry Players: Distribution by Source of Cell
Table 39.19 Non-Industry Players: Distribution by Scale of Operation
Table 39.20 Non-Industry Players: Distribution by Type of Additional Service Offered
Table 39.21 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities / Certifications
Table 39.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Regulatory Authorities / Certifications
Table 39.23 WuXi AppTec (parent company of Advanced Therapies): Annual Revenues, Since FY 2022 (RMB Billion)
Table 39.24 AGC Biologics: Annual Revenues, Since FY 2022 (JPY Billion)
Table 39.25 Catalent: Annual Revenues, Since FY 2021 (USD Billion)
Table 39.26 Charles River Laboratories: Annual Revenues, Since FY 2022 (USD Billion)
Table 39.27 ImmunityBio: Annual Revenues, Since FY 2023 (USD Million)
Table 39.28 Merck KGaA (Parent company of Merck Millipore): Annual Revenues, Since FY 2022 (EUR Billion)
Table 39.29 Thermo Fisher Scientific: Annual Revenues, Since FY 2022 (JPY Billion)
Table 39.30 Evotec: Annual Revenues, Since FY 2022 (EUR Million)
Table 39.31 Lonza: Annual Revenues, Since FY 2022 (CHF Billion)
Table 39.32 Sartorius: Annual Revenues, Since FY 2022 (EUR Billion)
Table 39.33 Astellas Pharma: Annual Revenues, Since FY 2022 (YEN Billion)
Table 39.34 Pharmaron: Annual Revenues, Since FY 2022 (RMB Billion)
Table 39.35 Takara Bio: Annual Revenues, Since FY 2023 (YEN Billion)
Table 39.36 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2021
Table 39.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
Table 39.38 Clinical Trial Analysis: Distribution by Trial Status
Table 39.39 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 39.40 Clinical Trial Analysis: Distribution by Trial Phase
Table 39.41 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 39.42 Clinical Trial Analysis: Distribution by Patient Gender
Table 39.43 Clinical Trial Analysis: Distribution by Type of Allocation
Table 39.44 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 39.45 Clinical Trial Analysis: Distribution by Type of Masking
Table 39.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 39.47 Most Active Industry Players: Distribution by Number of Registered Trials
Table 39.48 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 39.49 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 39.50 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 39.51 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 39.52 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Table 39.53 Partnerships and Collaborations: Distribution by Type of Partnership
Table 39.54 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 39.55 Partnerships and Collaborations: Distribution by Type of Immune Cell
Table 39.56 Partnerships and Collaborations: Distribution by Scale of Operation
Table 39.57 Most Active Players: Distribution by Number of Partnerships
Table 39.58 Partnerships and Collaborations: Local and International Agreements
Table 39.59 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 39.60 Recent Expansions: Cumulative Year-wise Trend, Since 2021
Table 39.61 Recent Expansions: Distribution by Type of Expansion
Table 39.62 Recent Expansions: Distribution by Year and Type of Expansion
Table 39.63 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 39.64 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 39.65 Recent Expansions: Distribution by Type of Expansion and Location of Headquarters (Country)
Table 39.66 Recent Expansions: Distribution by Type of Immune Cell
Table 39.67 Recent Expansions: Distribution by Type of Expansion and Type of Immune Cell
Table 39.68 Recent Expansions: Distribution by Scale of Operation
Table 39.69 Most Active Players: Distribution by Number of Expansions
Table 39.70 Most Active Players: Distribution by Area of Expansion (in sq. ft)
Table 39.71 Big Pharma Initiatives: Distribution by Year of Initiative
Table 39.72 Big Pharma Initiatives: Distribution by Type of Initiative
Table 39.73 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 39.74 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Table 39.75 Big Pharma Initiatives: Distribution by Type of Partnership
Table 39.76 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
Table 39.77 Big Pharma Initiatives: Distribution by Type of Facility Expansion
Table 39.78 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Facility Expansion
Table 39.79 Big Pharma Initiatives: Distribution of Big Pharma Players by Region of Facility Expansion
Table 39.80 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
Table 39.81 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Funding and Investment
Table 39.82 Big Pharma Initiatives: Distribution by Type of Immune Cell
Table 39.83 Big Pharma Initiatives: Distribution by Scale of Operation
Table 39.84 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
Table 39.85 Big Pharma Initiatives Summary
Table 39.86 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing: Distribution by Range of Installed Capacity
Table 39.87 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
Table 39.88 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Table 39.89 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 39.90 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Table 39.91 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 39.92 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
Table 39.93 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
Table 39.94 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
Table 39.95 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Table 39.96 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Table 39.97 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 39.98 Global Installed Capacity of Non-Industry Players for Cell Therapy Manufacturing: Distribution by Range of Number of Cleanrooms
Table 39.99 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Table 39.100 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 39.101 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
Table 39.102 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
Table 39.103 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Table 39.104 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (Number of Patients)
Table 39.105 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
Table 39.106 Global Clinical Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 39.107 Clinical Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 39.108 Clinical Demand for Cell Therapy Manufacturing: Distribution by Key Geographical Regions, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 39.109 Global Commercial Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 39.110 Commercial Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 39.111 Commercial Demand for Cell Therapy Manufacturing: Distribution by Key Geographical Regions, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 39.112 Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.113 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
Table 39.114 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Table 39.115 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
Table 39.116 Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.117 Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.118 Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.119 Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.120 Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.121 Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.122 Cell Therapy Manufacturing Market: Distribution by Source of Cells
Table 39.123 Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.124 Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.125 Cell Therapy Manufacturing Market: Distribution by Origin of Cells
Table 39.126 Cell Therapy Manufacturing Market for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.127 Cell Therapy Manufacturing Market for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.128 Cell Therapy Manufacturing Market for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.129 Cell Therapy Manufacturing Market for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.130 Cell Therapy Manufacturing Market for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.131 Cell Therapy Manufacturing Market for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.132 Cell Therapy Manufacturing Market: Distribution by Technology
Table 39.133 Cell Therapy Manufacturing Market for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.134 Cell Therapy Manufacturing Market for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.135 Cell Therapy Manufacturing Market for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.136 Cell Therapy Manufacturing Market for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.137 Cell Therapy Manufacturing Market for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.138 Cell Therapy Manufacturing Market for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.139 Cell Therapy Manufacturing Market: Distribution by Scale of Operation
Table 39.140 Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.141 Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.142 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
Table 39.143 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.144 Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.145 Cell Therapy Manufacturing Market: Distribution by Key Geographical Regions
Table 39.146 Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.147 Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.148 Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.149 Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.150 Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.151 Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.152 Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.153 Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.154 Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.155 Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.156 Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.157 Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.158 Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.159 Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.160 Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.161 Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.162 Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.163 Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.164 Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.165 Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.166 Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.167 Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.168 Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.169 Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.170 Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.171 Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.172 Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.173 Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.174 Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.175 Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.176 Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.177 Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.178 Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.179 Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.180 Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Table 39.181 Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends (I / II)
Figure 5.3 Executive Summary: Market Trends (II / II)
Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Classification of Advanced Therapy Medicinal Products (ATMPs)
Figure 6.2 Decentralized Manufacturing: Process Model
Figure 6.3 Cell Therapy Manufacturing: Type of Manufacturer
Figure 6.4 Cell Therapies: Challenges and Drivers
Figure 6.5 Cell Therapies: Potency as a Critical Quality Attribute
Figure 6.6 Cell Therapy Manufacturing: Supply Chain Model
Figure 7.1 Industry Players: Distribution by Year of Establishment
Figure 7.2 Industry Players: Distribution by Company Size
Figure 7.3 Industry Players: Distribution by Location of Headquarters (Region)
Figure 7.4 Industry Players: Distribution by Location of Headquarters (Country)
Figure 7.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
Figure 7.6 Industry Players: Distribution by Location of Manufacturing Facility (Region)
Figure 7.7 Industry Players: Distribution by Location of Manufacturing Facility (Country)
Figure 7.8 Industry Players: Distribution by Type of Immune Cell Offered
Figure 7.9 Industry Players: Distribution by Source of Cells
Figure 7.10 Industry Players: Distribution by Scale of Operation
Figure 7.11 Industry Players: Distribution by Type of Additional Service Offered
Figure 8.1 Non-Industry Players: Distribution by Year of Establishment
Figure 8.2 Non-Industry Players: Distribution by Location of Headquarters (Region)
Figure 8.3 Non-Industry Players: Distribution by Location of Headquarters (Country)
Figure 8.4 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
Figure 8.5 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
Figure 8.6 Non-Industry Players: Distribution by Type of Immune Cell Offered
Figure 8.7 Non-Industry Players: Distribution by Source of Cell
Figure 8.8 Non-Industry Players: Distribution by Scale of Operation
Figure 8.9 Non-Industry Players: Distribution by Type of Additional Service Offered
Figure 9.1 Cell Therapy Manufacturing (Industry Players): Distribution by Regulatory Authorities / Certifications
Figure 9.2 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Regulatory Authorities / Certifications
Figure 11.1 Key Considerations for Automating Cell Therapy Manufacturing Process
Figure 11.2 Requirements to Implement Closed Systems in Cell Therapy Manufacturing Processes
Figure 11.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
Figure 11.4 Advantages and Disadvantages of Single-Use System
Figure 11.5 Growth Drivers and Roadblocks to the Automated and Closed Systems
Figure 11.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 11.7 Cell Therapy Manufacturing: Comparison Between Manual and Automated Processes
Figure 11.8 Cell Therapy Manufacturing: Comparative Analysis of Manual and Automated Processes Based on Affiliated Costs
Figure 12.1 WuXi AppTec (parent company of Advanced Therapies): Annual Revenues, Since FY 2022 (RMB Billion)
Figure 12.2 AGC Biologics: Annual Revenues, Since FY 2022 (JPY Billion)
Figure 12.3 Catalent: Annual Revenues, Since FY 2021 (USD Billion)
Figure 12.4 Charles River Laboratories: Annual Revenues, Since FY 2022 (USD Billion)
Figure 12.5 ImmunityBio: Annual Revenues, Since FY 2023 (USD Million)
Figure 12.6 Merck KGaA (Parent company of Merck Millipore): Annual Revenues, Since FY 2022 (EUR Billion)
Figure 12.7 Thermo Fisher Scientific: Annual Revenues, Since FY 2022 (JPY Billion)
Figure 12.8 Evotec: Annual Revenues, Since FY 2022 (EUR Million)
Figure 12.9 Lonza: Annual Revenues, Since FY 2022 (CHF Billion)
Figure 12.10 Sartorius: Annual Revenues, Since FY 2022 (EUR Billion)
Figure 12.11 Astellas Pharma: Annual Revenues, Since FY 2022 (YEN Billion)
Figure 12.12 Pharmaron: Annual Revenues, Since FY 2022 (RMB Billion)
Figure 12.13 Takara Bio: Annual Revenues, Since FY 2023 (YEN Billion)
Figure 13.1 City of Hope: Type of Additional Service Offered
Figure 13.2 Clinical Cell and Vaccine Production Facility (CVPF): Type of Additional Service Offered
Figure 13.3 Fraunhofer Institute for Cell Therapy and Immunology: Type of Additional Service Offered
Figure 13.4 Newcastle Advanced Therapies: Type of Additional Service Offered
Figure 13.5 NHS Blood and Transplant: Type of Additional Service Offered
Figure 13.6 Rayne Cell Therapy Suite (King's College London): Type of Additional Service Offered
Figure 13.7 Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility: Type of Additional Service Offered
Figure 15.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2021
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
Figure 15.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 15.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 15.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 15.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 15.9 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 15.10 Clinical Trial Analysis: Distribution by Type of Masking
Figure 15.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 15.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 15.14 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 15.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 15.16 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 16.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Figure 16.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 16.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 16.4 Partnerships and Collaborations: Distribution by Type of Immune Cell
Figure 16.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 16.6 Most Active Players: Distribution by Number of Partnerships
Figure 16.7 Partnerships and Collaborations: Local and International Agreements
Figure 16.8 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 17.1 Recent Expansions: Cumulative Year-wise Trend, Since 2021
Figure 17.2 Recent Expansions: Distribution by Type of Expansion
Figure 17.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 17.4 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 17.5 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 17.6 Recent Expansions: Distribution by Type of Expansion and Location of Headquarters (Country)
Figure 17.7 Recent Expansions: Distribution by Type of Immune Cell
Figure 17.8 Recent Expansions: Distribution by Type of Expansion and Type of Immune Cell
Figure 17.9 Recent Expansions: Distribution by Scale of Operation
Figure 17.10 Most Active Players: Distribution by Number of Expansions
Figure 17.11 Most Active Players: Distribution by Area of Expansion (in sq. ft)
Figure 18.1 Big Pharma Initiatives: Distribution by Year of Initiative
Figure 18.2 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 18.3 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Figure 18.4 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Figure 18.5 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 18.6 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
Figure 18.7 Big Pharma Initiatives: Distribution by Type of Facility Expansion
Figure 18.8 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Facility Expansion
Figure 18.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Region of Facility Expansion
Figure 18.10 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
Figure 18.11 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Funding and Investment
Figure 18.12 Big Pharma Initiatives: Distribution by Type of Immune Cell
Figure 18.13 Big Pharma Initiatives: Distribution by Scale of Operation
Figure 18.14 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
Figure 18.15 Big Pharma Initiatives Summary
Figure 19.1 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing: Distribution by Range of Installed Capacity
Figure 19.2 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
Figure 19.3 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Figure 19.4 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 19.5 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Figure 19.6 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 19.7 Global Installed Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
Figure 19.8 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
Figure 19.9 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
Figure 19.10 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 19.11 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Figure 19.12 Global Installed Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 19.13 Global Installed Capacity of Non-Industry Players for Cell Therapy Manufacturing: Distribution by Range of Number of Cleanrooms
Figure 19.14 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Figure 19.15 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 19.16 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
Figure 19.17 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
Figure 19.18 Global Installed Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 20.1 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (Number of Patients)
Figure 20.2 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
Figure 20.3 Global Clinical Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.4 Clinical Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.5 Clinical Demand for Cell Therapy Manufacturing: Distribution by Key Geographical Regions, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.6 Global Commercial Demand for Cell Therapy Manufacturing, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.7 Commercial Demand for Cell Therapy Manufacturing: Distribution by Type of Cell Therapy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 20.8 Commercial Demand for Cell Therapy Manufacturing: Distribution by Key Geographical Regions, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 21.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 22.1 Make versus Buy Decision Making Framework
Figure 22.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 23.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 23.3 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 23.4 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 23.5 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 23.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 24.1 Cell Therapy Manufacturing: SWOT Analysis
Figure 24.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 25.1 Survey Insights: Distribution of Respondents by Type of Organization
Figure 25.2 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
Figure 25.3 Survey Insights: Distribution by Designation and Seniority of Respondents
Figure 25.4 Survey Insights: Distribution by Type of Cell Therapy
Figure 25.5 Survey Insights: Distribution by Scale of Operation
Figure 25.6 Survey Insights: Distribution by Source of Cells
Figure 25.7 Survey Insights: Distribution by Cell Culture System
Figure 26.1 Global Cell Therapy Manufacturing Market, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.2 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
Figure 26.3 Global Cell Therapy Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Figure 27.1 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy
Figure 27.2 Cell Therapy Manufacturing Market for CAR-T Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.3 Cell Therapy Manufacturing Market for Stem Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.4 Cell Therapy Manufacturing Market for TCR Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.5 Cell Therapy Manufacturing Market for TIL Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.6 Cell Therapy Manufacturing Market for Dendritic Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.7 Cell Therapy Manufacturing Market for Other Cell Therapies, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.1 Cell Therapy Manufacturing Market: Distribution by Source of Cells
Figure 28.2 Cell Therapy Manufacturing Market for Autologous Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.3 Cell Therapy Manufacturing Market for Allogeneic Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.1 Cell Therapy Manufacturing Market: Distribution by Origin of Cells
Figure 29.2 Cell Therapy Manufacturing Market for Induced Pluripotent Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.3 Cell Therapy Manufacturing Market for Bone Marrow, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.4 Cell Therapy Manufacturing Market for Umbilical Cord, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.5 Cell Therapy Manufacturing Market for Adipose Tissue, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.6 Cell Therapy Manufacturing Market for Neural Stem Cells, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.7 Cell Therapy Manufacturing Market for Others, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.1 Cell Therapy Manufacturing Market: Distribution by Technology
Figure 30.2 Cell Therapy Manufacturing Market for Somatic Cell Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.3 Cell Therapy Manufacturing Market for 3D Bioprinting Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.4 Cell Therapy Manufacturing Market for Cell Immortalization Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.5 Cell Therapy Manufacturing Market for Viral Vector Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.6 Cell Therapy Manufacturing Market for Genome Editing Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.7 Cell Therapy Manufacturing Market for Cell Plasticity Technology, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.1 Cell Therapy Manufacturing Market: Distribution by Scale of Operation
Figure 31.2 Cell Therapy Manufacturing Market for Clinical Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.3 Cell Therapy Manufacturing Market for Commercial Scale, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 32.1 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer
Figure 32.2 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 32.3 Cell Therapy Manufacturing Market for In-House Manufacturers, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.1 Cell Therapy Manufacturing Market: Distribution by Key Geographical Regions
Figure 33.2 Clinical Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.3 Clinical Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.4 Clinical Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.5 Clinical Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.6 Clinical Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.7 Clinical Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.8 Clinical Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.9 Clinical Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.10 Clinical Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.11 Clinical Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.12 Clinical Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.13 Clinical Cell Therapy Manufacturing Market in Singapore, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.14 Clinical Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.15 Clinical Cell Therapy Manufacturing Market in Israel, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.16 Clinical Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.17 Clinical Cell Therapy Manufacturing Market in Taiwan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.18 Clinical Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.19 Clinical Cell Therapy Manufacturing Market in Argentina, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.20 Clinical Cell Therapy Manufacturing Market in South Africa, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.21 Commercial Cell Therapy Manufacturing Market in North America, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.22 Commercial Cell Therapy Manufacturing Market in the US, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.23 Commercial Cell Therapy Manufacturing Market in Canada, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.24 Commercial Cell Therapy Manufacturing Market in Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.25 Commercial Cell Therapy Manufacturing Market in Germany, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.26 Commercial Cell Therapy Manufacturing Market in France, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.27 Commercial Cell Therapy Manufacturing Market in the UK, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.28 Commercial Cell Therapy Manufacturing Market in Italy, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.29 Commercial Cell Therapy Manufacturing Market in Spain, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.30 Commercial Cell Therapy Manufacturing Market in Rest of Europe, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.31 Commercial Cell Therapy Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.32 Commercial Cell Therapy Manufacturing Market in China, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.33 Commercial Cell Therapy Manufacturing Market in Japan, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.34 Commercial Cell Therapy Manufacturing Market in Australia, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.35 Commercial Cell Therapy Manufacturing Market in India, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.36 Commercial Cell Therapy Manufacturing Market in South Korea, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 33.37 Commercial Cell Therapy Manufacturing Market in Brazil, Historical Trends (since 2023) and Forecasted Estimates (till 2035) (USD Billion)
Figure 37.1 Conclusion: Market Landscape (Industry Players)
Figure 37.2 Conclusion: Market Landscape (Non-Industry Players)
Figure 37.3 Conclusion: Clinical Trial Analysis
Figure 37.4 Conclusion: Partnerships and Collaborations
Figure 37.5 Conclusion: Recent Expansions
Figure 37.6 Conclusion: Big Pharma Initiatives
Figure 37.7 Conclusion: Capacity Analysis
Figure 37.8 Conclusion: Demand Analysis
Figure 37.9 Conclusion: Total Cost of Ownership
Figure 37.10 Conclusion: Market Sizing and Opportunity Analysis

Cell Therapy Manufacturing Market (7th Edition) by Type of Cell Therapy, Source of Cells, Origin of Cells, Technology, Scale of Operation, Type of Manufacturer, Key Geographical Regions - Trends and Forecast Till 2035

Description

Table of Contents

List of Tables

CELL THERAPY MANUFACTURING MARKET: OVERVIEW

Example Players in Cell Therapy Manufacturing Market

CELL THERAPY MANUFACTURING MARKET: RESEARCH COVERAGE

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

8. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

9. REGULATORY LANDSCAPE

10. CASE STUDY: ROADMAPS FOR OVERCOMING CHALLENGES RELATED TO CELL THERAPY MANUFACTURING

11. CASE STUDY: AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

12. COMPANY PROFILES: INDUSTRY PLAYERS

13. COMPANY PROFILES: NON-INDUSTRY PLAYERS

14. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING

15. CLINICAL TRIAL ANALYSIS

16. PARTNERSHIPS AND COLLABORATIONS

17. RECENT EXPANSIONS

18. BIG PHARMA INITIATIVES

19. CAPACITY ANALYSIS

20. DEMAND ANALYSIS

21. COST PRICE ANALYSIS

22. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

23. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS

24. SWOT ANALYSIS

25. SURVEY ANALYSIS

26. GLOBAL CELL THERAPY MANUFACTURING MARKET

27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY

28. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS

29. CELL THERAPY MANUFACTURING MARKET, BY ORIGIN OF CELLS

30. CELL THERAPY MANUFACTURING MARKET, BY TECHNOLOGY

31. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION

32. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER

33. CELL THERAPY MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

34. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

35. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: EUROPE

36. CELL THERAPY MANUFACTURING MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

37. CONCLUDING REMARKS

38. EXECUTIVE INSIGHTS

39. APPENDIX I: TABULATED DATA

40. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures